Skip to main content
NCBI home page
British Medical Journal logoLink to British Medical Journal
. 1972 Mar 18;1(5802):741–742. doi: 10.1136/bmj.1.5802.741

Treatment for Parkinsonism, other than levodopa.

PMCID: PMC1787626  PMID: 5015332

Full text

PDF
741

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bleidner W. E., Harmon J. B., Hewes W. E., Lynes T. E., Hermann E. C. Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther. 1965 Dec;150(3):484–490. [PubMed] [Google Scholar]
  2. ENGLAND A. C., Jr, SCHWAB R. S. Parkinson's syndrome. N Engl J Med. 1961 Oct 26;265:837–concl. doi: 10.1056/NEJM196110262651706. [DOI] [PubMed] [Google Scholar]
  3. Fieschi C., Nardini M., Casacchia M., Tedone M. E. Amantadine for Parkinson's disease. Lancet. 1970 May 2;1(7653):945–946. doi: 10.1016/s0140-6736(70)91065-2. [DOI] [PubMed] [Google Scholar]
  4. Fieschi C., Nardini M., Casacchia M., Tedone M. E., Reitano M., Robotti E. Amantadine versus L-2 dopa and amatadine plus L-dopa. Lancet. 1970 Jul 18;2(7664):154–155. doi: 10.1016/s0140-6736(70)92742-x. [DOI] [PubMed] [Google Scholar]
  5. Godwin-Austen R. B., Frears C. C., Bergmann S., Parkes J. D., Knill-Jones R. P. Combined treatment of parkinsonism with L-dopa and amantadine. Lancet. 1970 Aug 22;2(7669):383–385. doi: 10.1016/s0140-6736(70)90002-4. [DOI] [PubMed] [Google Scholar]
  6. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  7. Hughes R. C., Polgar J. G., Weightman D., Walton J. N. Levodopa in Parkinsonism: the effects of withdrawal of anticholinergic drugs. Br Med J. 1971 May 29;2(5760):487–491. doi: 10.1136/bmj.2.5760.487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hunter K. R., Stern G. M., Laurence D. R., Armitage P. Amantadine in parkinsonism. Lancet. 1970 May 30;1(7657):1127–1129. doi: 10.1016/s0140-6736(70)91210-9. [DOI] [PubMed] [Google Scholar]
  9. Hunter K. R., Stern G. M., Laurence D. R., Armitage P. Combined treatment of parkinsonism with L-dopa and amantadine. Lancet. 1970 Sep 12;2(7672):566–566. doi: 10.1016/s0140-6736(70)91365-6. [DOI] [PubMed] [Google Scholar]
  10. Mann D. C., Pearce L. A., Waterbury L. D. Amantadine for Parkinson's disease. Neurology. 1971 Sep;21(9):958–962. doi: 10.1212/wnl.21.9.958. [DOI] [PubMed] [Google Scholar]
  11. PORTEOUS H. B., ROSS D. N. Mental symptoms in parkinsonism following benzhexol hydrochloride therapy. Br Med J. 1956 Jul 21;2(4985):138–140. doi: 10.1136/bmj.2.4985.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Parkes J. D., Calver D. M., Zilkha K. J., Knill-Jones R. P. Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet. 1970 Feb 7;1(7641):259–262. doi: 10.1016/s0140-6736(70)90634-3. [DOI] [PubMed] [Google Scholar]
  13. Parkes J. D., Knill-Jones R. P., Clements P. J. L-dopa and amantadine hydrochloride in extra-pyramidal disorders. Postgrad Med J. 1971 Feb;47(544):116–119. doi: 10.1136/pgmj.47.544.116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Parkes J. D., Zilkha K. J., Marsden P., Baxter R. C., Knill-Jones R. P. Amantadine dosage in treatment of Parkinson's disease. Lancet. 1970 May 30;1(7657):1130–1133. doi: 10.1016/s0140-6736(70)91211-0. [DOI] [PubMed] [Google Scholar]
  15. Stromberg U., Svensson T. H., Waldeck B. On the mode of action of amantadine. J Pharm Pharmacol. 1970 Dec;22(12):959–962. doi: 10.1111/j.2042-7158.1970.tb08487.x. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES